Adding androgen deprivation therapy to external beam radiotherapy may result in better survival than adding a brachytherapy boost in men with intermediate- and high-risk prostate cancer, network meta-analysis data suggest.
Men with metastatic castration-resistant prostate cancer (mCRPC) who carry the CC genotype of the HSD3B1 c.1245A>C variant have worse responses to first-line abiraterone and enzalutamide than those with an AA or AC genotype, research shows.
The phase 3 IMbassador250 trial has failed to show any significant improvement in metastatic castration-resistant prostate cancer outcomes with the addition of atezolizumab to enzalutamide.
Stereotactic ablative radiotherapy is associated with a significantly lower risk for disease progression at 6 months relative to observation in men with oligometastatic prostate cancer, phase 2 study data show.
Prospective data now confirm that White men with low-volume metastatic castration-sensitive prostate cancer who have the adrenal-permissive HSD3B1 genotype have poorer outcomes than those with the adrenal-restrictive genotype.
US researchers have developed predictive models that could help identify men with prostate cancer who are likely to undergo pathologic downgrading after radical prostatectomy and therefore may be suitable candidates for active surveillance.
A combined approach using both MRI-targeted and systematic biopsy provides improved diagnostic accuracy for the detection of prostate cancer versus either strategy alone, say the Trio researchers.
The addition of pembrolizumab to enzalutamide has “modest activity” against metastatic castration-resistant prostate cancer that has become resistant to enzalutamide, say the KEYNOTE-199 researchers.
Abiraterone is associated with improved quality of life relative to docetaxel in men with hormone-naïve prostate cancer, shows an analysis of contemporaneously randomized participants of the STAMPEDE trial.
The combination of cabozantinib and atezolizumab has antitumor activity and a manageable safety profile in men with metastatic castration-resistant prostate cancer, indicate preliminary trial data.
The patient-reported outcomes from the CARD trial of third-line cabazitaxel in men with metastatic castration-resistant prostate cancer add support for using the taxane in this setting, say researchers.
The 8-year results from the phase 3 CHHiP trial have confirmed the noninferiority of moderately hypofractionated radiotherapy delivering 60 Gy in 20 fractions to the conventional regimen for the control of localized prostate cancer.
Metastasis-directed therapy for oligometastatic recurrent prostate cancer continues to be associated with better androgen deprivation therapy-free survival relative to surveillance at 5 years, show follow-up findings from the STOMP trial.
Combining a single nucleotide polymorphism-based genetic risk score for prostate cancer with family history could improve the stratification of inherited risk and help personalize screening strategies, research suggests.
Real-world data show comparable patient reported functional outcomes and health-related quality of life between nonmetastatic prostate cancer patients who were treated with moderately hypofractionated or conventionally fractionated radiation therapy.
The risk for clinically significant prostate cancer rises with age, report researchers who believe that this should be taken into account in the optimization of screening practices.